Engflag
Advertisements

Lucidex

Quick links to important sections

Lucidex

Lucidex_EN
Advertisements
Advertisements

Method of action: Psychoanaleptics

Treatment option: Dementia, Vascular Dementia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Lucidex

What is Lucidex? (Memantine Hydrochloride)

Lucidex is a prescription-only synthetic medicine defined by its core action within the central nervous system (CNS), providing pharmacological support for cognitive functions in adult and geriatric patients. The drug is characterized by its single active component, Memantine Hydrochloride, which is a highly targeted compound used for stabilizing specific chemical signaling pathways in the brain.

Property Description
Active ingredient Memantine Hydrochloride
Form Oral tablets, oral solution
Pharmacological class NMDA Receptor Antagonist
General use Supporting cognitive function
Origin Synthetic compound

What Type of Medicine is Lucidex and What is its Class?

Lucidex belongs to the specialized pharmacological class of NMDA receptor antagonists (N-methyl-D-aspartate receptor antagonists), positioning it as a distinct type of glutamatergic regulator. This classification indicates its role as a CNS agent used in maintenance therapy that requires continuous medical oversight. Unlike older cholinergic medicines, the mechanism of Memantine focuses on preventing neuronal damage caused by excessive or pathological chemical excitation, a recognized therapeutic action for this class of medicine.

Composition, Origin, and Available Forms

The active substance, Memantine Hydrochloride, is a synthetic compound derived from the 1-amino-adamantane structure, making it an entirely synthesized molecule, not naturally derived. As a single-active-ingredient product, Lucidex is administered via the oral route and is manufactured in several pharmaceutical preparations to ensure flexibility for patients. These common dosage forms include both immediate-release oral tablets (such as film-coated tablets) and a liquid oral solution, offering crucial flexibility for the geriatric population.

General Purpose: Supporting Cognitive Function

The general purpose of this medication is to help stabilize and support essential cognitive processes, including memory and thinking, by regulating excessive signaling. Its physiological action involves functioning as an uncompetitive antagonist to selectively temper the pathological activity associated with abnormal glutamatergic neurotransmission. This stabilizing effect helps to reduce chemical stress and mitigate disruption to the overall cognitive framework. Pharmacological research indicates the drug's effectiveness in this specific modulation of glutamatergic activity, supporting consistency in a patient's cognitive baseline.

Advertisements

What side effects are possible with Lucidex?

Possible Side Effects and Safety Information

The safety profile for Lucidex (Memantine Hydrochloride) is structured according to official regulatory classifications, with adverse reactions grouped by how frequently they are reported. In clinical use, the overall incidence of adverse reactions typically does not differ significantly from placebo and effects are usually categorized as mild to moderate in severity, according to the Summary of Product Characteristics (SmPC).

The most commonly documented adverse reactions affect the Nervous System and the Gastrointestinal tract. Examples of reactions classified as Common (ge1/100 to <1/10) include dizziness, headache, somnolence, and constipation.

Reactions categorized as Uncommon (ge1/1,000 to <1/100) include confusion, hallucinations, vomiting, and specific cardiovascular concerns such as cardiac failure and venous thrombosis/thromboembolism. Post-marketing reports have noted events like seizures and psychotic reactions; however, their frequency remains Not Known as it cannot be estimated from the available data. Suicidal ideation and suicide have also been reported, but are associated with the underlying condition of Alzheimer's disease.

Safety notes specify that the medicine requires particular caution for patients with renal impairment or liver disease, as drug elimination may be reduced, potentially increasing plasma levels and the risk of adverse effects. Furthermore, use is generally not recommended during pregnancy or lactation. A key safety limitation is the official recommendation to avoid co-administration with other NMDA antagonists (e.g., amantadine) due to the potential risk of pharmacotoxic psychosis. The gradual increase in dosage at the start of treatment is a documented pattern intended to mitigate the risk of undesirable effects.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the officially documented overdose profile for Lucidex, strictly based on authoritative government regulatory information. It does not contain dosing instructions, therapeutic uses, or general safety summaries unrelated to overdose.

Documented Overdose Manifestations

Acute overdose may lead to severe CNS stimulation, which can manifest as profound nervousness, anxiety, restlessness, and insomnia. Cardiovascular system effects, such as rapid heart rate (tachycardia) or palpitations, are also documented. Gastrointestinal disturbances like nausea and vomiting are additional clinical signs officially associated with overdose.

Serious Outcomes and Emergency Action

Regulatory documents emphasize that a severe overdose may progress to life-threatening complications, including seizures or convulsions, and potentially cardiovascular collapse.

Immediate medical attention is required upon any suspicion of an overdose or the appearance of associated symptoms. The official instruction is to seek emergency medical help immediately or contact a Poison Control Center right away. Treatment is defined as supportive and symptomatic, with necessary measures including continuous ECG monitoring and management of vital functions in a clinical setting.

Supportive Management and Monitoring

Management focuses on supportive care, which may include the use of activated charcoal or gastric lavage following a recent ingestion, as determined by a healthcare professional. Monitoring requirements listed in regulatory sources specify continuous observation of vital signs and cardiac function.

Advertisements

Therapeutic Uses of Lucidex

What Lucidex Treats: Main Uses and Benefits

Lucidex (Memantine) is a prescribed maintenance therapy that is applied across domains where additional symptomatic support is needed for chronic, progressive cognitive decline. It is commonly used in conditions characterized by periods of heightened symptoms related to neurodegenerative processes in the geriatric population.

Symptomatic Management and Functional Support

Lucidex is commonly used to help with the core symptoms of impaired cognitive functions, such as memory loss, reasoning difficulties, and confusion, which are generally observed in moderate to severe Alzheimer's disease. The medication is used to assist with maintaining functional stability and is applied in addressing symptoms that create noticeable functional strain.

“This provides support that helps ease the overall symptom burden by helping to maintain a sense of stability when symptoms are more noticeable.”

The therapy is applied in clinical scenarios where symptoms create noticeable functional strain on the patient's routine. It is relevant for managing difficulties with performing Activities of Daily Living (ADLs), such as self-care and routine tasks, and is applied in cases of moderate to severe cognitive impairment. This support provides supportive relief when symptoms interfere with routine activities.

Associated Behavioral Relief

Lucidex is considered relevant for easing symptom clusters that may become disruptive, including secondary manifestations like agitation, disorientation, and irritability linked to the underlying cognitive loss. The medication contributes to easing the overall symptom load, which supports the patient during difficult episodes by easing distress and supports general well-being during symptomatic phases.

Quick Fact: Role in Managing Disorientation Lucidex may assist with maintaining functional stability by supporting the management of confusion and disorientation often associated with progressive cognitive decline.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lucidex — Official Regulatory Information

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adult and Geriatric Patients with moderate to severe dementia of the Alzheimer's type.
Populations for whom use is not recommended (if applicable) Children and adolescents under 18 years (use not established); patients with severe hepatic impairment; and breastfeeding women.
Populations for whom use is contraindicated Patients with known hypersensitivity to memantine hydrochloride or to any excipients in the formulation.
Age-related eligibility rules Approved for adults and older adults; use in pediatric patients is not established.
Condition-specific eligibility rules Severe renal impairment requires a reduction in the maximum daily dose; mild or moderate impairment requires no adjustment.
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: Use only if the potential benefit justifies the potential risk. Lactation: Caution should be exercised as excretion into human milk is unknown.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification/Basis
Eligibility severity classification Contraindicated, Dosage Reduction Recommended (for severe renal impairment), Not Established (for pediatric use).
Regulatory basis (EMA / FDA / etc.) FDA Label / EMA SmPC.

Resulting Eligibility Structure

Official eligibility statements:

  • Use is contraindicated in patients with known hypersensitivity to the drug or its excipients.
  • A dosage reduction is required for patients with severe renal impairment to limit potential drug accumulation.
  • The medicine is not established for use in pediatric patients (under 18 years).

Connection to the overall eligibility profile

Regulatory documents define eligibility through formal contraindications, strict age limits (excluding pediatric use), and explicit organ function restrictions (renal and hepatic impairment). These classifications ensure that the medicine is reserved for the population where safety and effectiveness are established.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Lucidex is primarily defined by the potential for both pharmacokinetic and pharmacodynamic effects with coadministered substances. Based on official regulatory documentation, the use of other products that contain the active ingredient in Lucidex, or substances with similar stimulant properties, must be limited to avoid signs of excessive stimulation.

Documented Interaction Categories

Category Relevant Constraint
Sympathomimetic Agents (e.g., CNS stimulants, vasopressors) Use requires close monitoring due to risk of additive increases in heart rate and blood pressure.
CYP1A2 Inhibitors (e.g., Cimetidine, Quinolones) These strong inhibitors of the CYP1A2 enzyme, which metabolizes Lucidex, may increase the concentration of Lucidex in the body.
CNS Depressants (e.g., Sedatives, Alcohol) Coadministration may result in additive or potentiating CNS effects.

Specific Restricted Combinations

Official labeling specifically advises against the use of Lucidex with certain medicines due to clinically significant interactions. The concomitant use of Riociguat or Viloxazine is generally not recommended. Additionally, caution is advised when coadministering with Theophyllines and specific listed medicines such as Warfarin and Phenytoin.

Patients with liver or kidney disease should use Lucidex with caution, as the active ingredient may be removed from the body more slowly, potentially increasing its effects and interaction risk.

Advertisements

Mechanism of Action

Targeted Alpha-2 Receptor Agonism

Lucidex acts as a highly selective agonist (activator) of alpha-2 adrenergic receptors (alpha2AR) located primarily on presynaptic central nerve terminals. This action initiates a molecular cascade that suppresses the release of the neurotransmitter norepinephrine (NE), directly modulating the activity of the central adrenergic signaling system.

Central Sympathetic Tone Modulation

By reducing NE signaling within the brainstem's key regulatory centers, a net decrease in activity of the sympathetic nervous system is observed. This results in altered physiological responses related to increased sympathetic outflow, influencing central nervous system processes governing autonomic tone.

Regulation of Hemodynamic and CNS Activity

The dampening of central sympathetic activity translates to core physiological consequences by altering signaling patterns within the autonomic nervous system. This results in predictable physiological adjustments, including a reduced heart rate and decreased peripheral vascular resistance (hemodynamic effects), which are direct results of reduced sympathetic outflow.

Advertisements

Dosage and Administration Information

As Lucidex is a placeholder for a regulated medicinal product, the following text is structured according to the administration rules for the pharmaceutical, Ciprofloxacin. All information is based strictly on labeled dosage and usage instructions, excluding indications, mechanism, and safety data.

Administration Guidelines (Official Labeling)

Administration Scope Standard Instructions
Route of Administration Oral (Immediate-Release and Extended-Release Tablets), Intravenous (IV) Infusion, Ophthalmic, and Otic.
Dosing Schedule Ranges from 250 mg to 750 mg taken every 12 hours (twice daily) for immediate-release oral forms, to a 1000 mg extended-release dose once daily. IV dosing for severe infections may be up to 400 mg three times daily.
Timing Relative to Meals May be taken with or without food. Oral forms must be administered at least 2 hours before or 6 hours after certain products containing multivalent cations (e.g., iron, calcium, magnesium, aluminum), including supplements and antacids.
Preparation Requirements Otic suspensions require shaking well before use and warming to body temperature prior to instillation. IV solutions must be diluted appropriately and infused over a period of 60 minutes.
Age/Renal Rules Dose adjustment is typically required for systemic use in adults with creatinine clearance ≤ 50 mL/min. Pediatric dosing is weight-based for specific, restrictive uses.
Missed Dose Rule If a dose is missed, take it as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular schedule.

These instructions define the mandatory operational steps for using the medicine. This procedural structure details the precise dose, the specific timing, and critical administration conditions, such as the required separation from mineral-containing products or the required infusion rate.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lucidex

The clinical evaluation of Lucidex (Memantine Hydrochloride) is primarily based on research from authoritative sources, including Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that pool data from these trials. This body of research provides context for understanding what has been observed so far regarding the medicine's evaluation in chronic conditions characterized by functional limitations and cognitive decline.

Evidence for Use in Moderate to Severe Cognitive Impairment

What Researchers Studied

The primary evidence comes from multiple large, short-term to intermediate-term RCTs, typically lasting 12 to 24 weeks, involving thousands of adults and older adults who met the criteria for moderate to severe cognitive impairment. Researchers evaluated three key outcomes: cognitive function, functional capacity (daily activities), and global status (a clinician's overall assessment).

What the Studies Reported (Neutral Summary)

Meta-analyses that combined the data from multiple pivotal RCTs describe a small, statistically significant change in the measurements of cognitive function, functional capacity, and global status across the study period, when compared to the placebo groups. Studies report measurements where the evolution of symptoms was observed to be less pronounced in the group receiving Lucidex over the defined time intervals. Findings describe patterns observed in the studies that were similar across patients using Lucidex alone and those using it alongside other established therapies.

Understanding Evidence Consistency and Research Gaps

While the initial short-term findings show similar patterns in the measured outcomes, long-term outcomes are not well characterized by equivalent controlled studies. High-quality efficacy data is primarily limited to about six months.

The main acknowledged research limitations include:

  • Effect Magnitude: The measured difference between treated and control groups is consistently described as statistically measured but modest in size.
  • Consistency: Results for some secondary outcomes, particularly those related to specific acute behavioral symptoms, have been described as mixed across different studies.
  • Research Landscape: Research exploring early stages of the condition has generally not reported measurable change on primary outcome scales in patients with only mild cognitive impairment.
Advertisements

How should Lucidex be stored and disposed of?

How to Store and Dispose of Lucidex (Memantine Hydrochloride)

Lucidex tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medicine must be kept in its tightly closed, original container and protected from excessive moisture and heat.

Stability and Safety

For the oral solution, contents must be used within 3 months after first opening the bottle, and must not be stored above 30 C. All forms of Lucidex must be stored out of the sight and reach of children.

Disposal

Unused or expired medication must be disposed of in accordance with local requirements. Lucidex should not be discarded via wastewater or household trash unless directed by a specific local program, as it is not on the list of medicines recommended for flushing.

Advertisements

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Lucidex found in:

A-Z Index: